Cedars-Sinai has created a lifelike model of the mysterious and fatal disease that could help identify a cause of the illness ...

Dr. Corcia heightens expertise behind PLL Therapeutics’ polypeptide delivery platform and development of world’s first blood biomarker to detect early onset of ALS  Appointment follows recent launch ...

An iPSC-based ALS-on-a-chip model that mimics disease progression and reveals altered glutamate signaling in motor neurons ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Carmen Iris Albaladejo told Newsweek that her husband "feels the weight of his life being taken from him piece by piece" following his diagnosis.

Cedars-Sinai has created a lifelike model of the mysterious and fatal disease that could help identify a cause of the illness ...

High-dose dazucorilant patients who went into the open-label extension saw an 84% lower risk of death over those who didn't take it at all..

The experimental ALS treatment usnoflast exhibited promising signs of slowed functional decline and improved breathing in a ...

Researchers wanted to see whether non-aerobic physical fitness, assessed by a sitting-rising test, could predict premature ...

Cedars-Sinai owns a minority stock interest in Emulate, the company that produces the study's microfluidic Organ-Chips. An officer of Cedars-Sinai also serves on Emulate's Board of Directors. C.N.S ...